Entrada Therapeutics, Inc. (TRDA) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -41.7M | -32.2M | -28.31M | -29.49M | -38.51M | -31.61M | -24.27M | 39.83M | -25.52M | -4.01M | -24.49M | -35.09M |
| Operating CF Margin % | -4765.14% | -2479.06% | -1754.21% | -1512.26% | -187.31% | -84.51% | -124% | 42.07% | -43.16% | -9.59% | -56% | -193.13% |
| Operating CF Growth % | -8.28% | -1.89% | -16.68% | -174.03% | -50.9% | -687.57% | 0.92% | 213.51% | -112.55% | 85.3% | 10.88% | -94.85% |
| Net Income | -39.72M | -39.16M | -44.13M | -43.1M | -17.35M | 1.13M | -14.03M | 55.03M | 23.5M | -9.54M | 35.46M | -25.93M |
| Depreciation & Amortization | 805K | -2.79M | 1.2M | 1.03M | 946K | 992K | 937K | 910K | 934K | 736K | 800K | 700K |
| Stock-Based Compensation | 0 | 4.36M | 0 | 5.05M | 5.09M | 4.7M | 4.86M | 4.62M | 3.73M | 3.84M | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 4.2M | 3.04M | 4.41M | -961K | -1.34M | -2.51M | -3.21M | -2.26M | -2.04M | -2M | 1.58M | 1.46M |
| Working Capital Changes | -6.98M | 2.35M | 10.21M | 8.49M | -25.85M | -35.92M | -12.82M | -18.47M | -51.65M | 2.95M | -62.33M | -11.32M |
| Change in Receivables | 390K | 19K | -16K | 864K | 1.64M | -1.08M | 5.07M | 69.84M | -71.64M | -853K | -1.28M | 2.55M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 641K | -877K | 1.31M | -321K | -1.91M | 2.85M | -314K | -886K | -655K | 2.41M | -1.36M | -4.38M |
| Cash from Investing | 26.99M | 29.12M | 49.11M | 33.8M | 4.78M | 53.37M | -82.93M | -24.38M | 26.15M | 19.04M | -3.74M | -113.26M |
| Capital Expenditures | -44K | 207K | 171K | -275K | -1.14M | -635K | -639K | -1.05M | -838K | -976K | -1.45M | -1.52M |
| CapEx % of Revenue | 5.03% | 15.94% | 10.59% | 14.1% | 5.56% | 1.7% | 3.27% | 1.1% | 1.42% | 2.33% | 3.31% | 8.38% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 100K | 192K | 8K | 337K | 350K | 1.4M | -11K | 101.37M | 206K | 690K | 368K | 443K |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 100K | 192K | 8K | 337K | 0 | 0 | -392K | 100M | 206K | 690K | 368K | 443K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 0 | 350K | 1.4M | 381K | 1.37M | 0 | 0 | 0 | 0 |
| Net Change in Cash | -14.61M | -2.89M | 20.8M | 4.64M | -33.37M | 23.16M | -107.2M | 116.82M | 834K | 15.72M | -27.86M | -147.91M |
| Free Cash Flow | -41.74M | -32M | -28.14M | -29.76M | -39.65M | -32.24M | -24.91M | 38.79M | -26.36M | -4.99M | -25.94M | -36.61M |
| FCF Margin % | -4770.17% | -2463.13% | -1743.62% | -1526.36% | -192.87% | -86.21% | -127.26% | 40.96% | -44.58% | -11.92% | -59.31% | -201.5% |
| FCF Growth % | -5.27% | 0.76% | -13% | -176.74% | -50.44% | -546.22% | 3.99% | 205.94% | -113.07% | 82.19% | 8.31% | -94.92% |
| FCF per Share | -1.00 | -0.77 | -0.68 | -0.72 | -0.97 | -0.75 | -0.61 | 1.09 | -0.76 | -0.15 | -0.75 | -1.10 |
| FCF Conversion (FCF/Net Income) | 1.05x | 0.82x | 0.64x | 0.68x | 2.22x | -27.94x | 1.73x | 0.72x | -1.09x | 0.42x | -0.69x | 1.35x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |